CAPTAINNCT06504056
Clinical Characteristics and Long-Term Outcomes of Left Ventricular Hypertrabeculation/Noncompaction
At risk: Primary completion moved at least 23 years 3 months later, primary endpoint(s) modified.
See at-risk trials from First Affiliated Hospital Xi'an Jiaotong University
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Dec 31, 2050 Show 11 more changesShow less
- Primary endpoint(s) modified
- Recruitment opened
- Enrollment increased: 2000 → 5000 participants
- Eligibility criteria expanded, about 192 words
- Interventions modified
- Trial arms changed: 3 → 2
- Start date changed from estimate of Oct 30, 2024 to Jul 20, 2024
- Secondary endpoints expanded, about 92 words
- Study description expanded, about 631 words
- Site details revised
- Study title shortened, about 3 words
- Minor Study description expanded, about 1 wordv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Patients of all ages with imaging-confirmed left ventricular hypertrabeculation/noncompaction (LVHT/LVNC), identified from existing clinical records between January 1, 2018, and the date of ethics approval of the amended protocol. Retrospectively available demographic, clinical, imaging, laboratory, treatment, and follow-up data will be collected. Patients may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Existing outcomes will be assessed using standardized definitions. No study-assigned interventions or additional clinical procedures will be performed.
Patients of all ages with imaging-confirmed LVHT/LVNC, prospectively enrolled following ethics approval of the amended protocol through December 31, 2045. Participants may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Baseline clinical and imaging information will be recorded, with follow-up planned at 6 months, 12 months, and annually from years 2 through 5. Clinical outcomes and longitudinal changes in cardiac structure and function will be assessed. Optional biospecimens may be collected during routine clinical care with appropriate consent. No study-assigned treatments or additional invasive procedures are required.
Sites
1 site in 1 country
- First Affiliated Hospital of Xi'an Jiantong UniversityXi'an, Shaanxi, China